SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Attention centers on speculation that SELLASs Phase 3 REGAL AML trial is nearing its final event trigger and subsequent topline analysis, with traders reacting to CEO commentary and favorable remarks from pharmaceutical-industry professionals. The community remains sharply divided: bulls view the prolonged survival and outside commentary as supportive, while bears question the trial design, delayed event timing, and likelihood of a successful readout.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStops preliminary second-quarter results and amended convertible-note exchange are driving attention, with traders weighing improved operating profitability against lower revenue, reduced cash, and dilution concerns. Unusual strength in the companys warrants has fueled speculation about a possible extension, hedging activity, or an upcoming move ahead of earnings, though no explanation is confirmed.

Helium is a decentralized machine network powered by a physical blockchain. The network is created by gateways who also double as miners on our network. These gateway operators can earn tokens based on coverage they provide as well as transaction fees gained from machines connecting to their gateway  Helium is a new cryptocurrency. Hotspots earn for providing and validating wireless coverage and when devices on the network connect to the internet through Hospots  Helium is mined and distributed to Hotspot Owners, Helium Inc, and investors. There is no pre-mine of Helium, and every month approximately 5,000,000 new Helium are minted.  At the end of each mining period, roughly every 30 to 60 mins, Helium is distributed according to the allocation shown:

Helium

Celina, Texass reported conversion of its city WiFi into Helium-powered carrier coverage is driving attention, with traders viewing the deployment and broader carrier-offload use case as evidence of real-world DePIN adoption. Bullish commenters expect continued momentum, while skeptics question token dilution, hotspot profitability, and whether network usage will translate into value for HNT holders.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

Anticipation of broader federal marijuana rescheduling to Schedule III, including an upcoming administrative-law recommendation, is driving attention as traders expect reduced tax burdens and improved institutional access for U.S. cannabis operators. The community remains largely bullish on Trulieves positioning and NYSE listing, while others warn that the catalyst is not yet finalized and cite profit-taking, overbought conditions, and post-earnings concerns.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Strong Phase 3 data for CAN-2409 in localized prostate cancer, along with anticipation of ASTRO findings and a planned Q4 BLA submission, is driving bullish attention. Traders see potential regulatory and pharmaceutical-partnership upside, while skeptics point to dilution risk, the unfiled BLA, profit-taking, and broader biotech momentumincluding enthusiasm around cancer-vaccine developmentsas competing factors.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Positive Phase 3 SHASTA-3 and SHASTA-4 results for plozasiran in severe hypertriglyceridemia are driving attention, after the studies met their primary and secondary endpoints and showed significant reductions in triglycerides and acute pancreatitis events. Traders are broadly bullish on the potential for a broader FDA label and commercial growth, though some remain cautious about valuation, competition from Ionis, and volatile options-driven trading.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Strait of Hormuz disruptions, tanker attacks and the broader Iran conflict are driving attention to USO, with traders debating whether constrained oil flows and low strategic reserves signal a sustained supply shock. The Venezuela oil agreement and reports of alternative shipping routes are viewed by bearish traders as potential offsets, though many argue added Venezuelan production would take years to materially affect supply.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Upcoming quarterly earnings are the dominant catalyst, with traders focused on whether Broadcoms AI custom-chip and networking demand will support stronger guidance. Bulls expect a beat and continued momentum from OpenAI and hyperscaler projects, while bears argue expectations are already elevated and remain concerned about debt, potential Google-related share loss, and another post-earnings selloff.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Canadian government backing for Xanadus quantum manufacturing and supply-chain expansion is driving attention, with traders debating whether additional federal and provincial support will follow. Bulls view the funding as validation of Xanadus photonic quantum strategy, while skeptics focus on dilution, execution risk, and the muted share-price reaction.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

NEREUSs U.S. commercial launch and ongoing development for GLP-1-related vomiting are driving attention, with traders viewing the program, alongside Bysanti and Vandas broader pipeline, as a potential strategic asset. The community is heavily speculating about a buyout by a large pharmaceutical company, while skeptics focus on cash burn, aggressive advertising spending, and possible dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence

Satellos reports six-month interim data showing SAT-3247 improved muscle composition, maintained strength, and remained well-tolerated in DMD.read more...

Satellos Bioscience Inc. (NASDAQ:MSLE) Given Average Rating of "Moderate Buy" by Analysts

Shares of Satellos Bioscience Inc. (NASDAQ:MSLE - Get Free Report) have earned an average rating of "Moderate Buy" from the six research firms that are presently covering the firm, MarketBeat...

Satellos Bioscience (NASDAQ:MSLE) Now Covered by Guggenheim

Guggenheim began coverage on shares of Satellos Bioscience in a research note on Tuesday. They issued a "buy" rating and a $23.00 price objective for the company...

Satellos Bioscience (NASDAQ:MSLE) Downgraded by Wall Street Zen to "Strong Sell"

Wall Street Zen downgraded Satellos Bioscience from a "sell" rating to a "strong sell" rating in a report on Saturday...

Satellos Bioscience Inc. (NASDAQ:MSLE) Receives Consensus Recommendation of "Hold" from Analysts

Satellos Bioscience Inc. (NASDAQ:MSLE - Get Free Report) has been assigned an average rating of "Hold" from the five ratings firms that are currently covering the firm, MarketBeat Ratings reports...

Satellos Bioscience (NASDAQ:MSLE) Now Covered by Analysts at Leerink Partners

Leerink Partners initiated coverage on shares of Satellos Bioscience in a research report on Monday. They set an "outperform" rating and a $20.00 price target on the stock...

Q2 EPS Estimate for Satellos Bioscience Increased by Analyst

Satellos Bioscience Inc. (NASDAQ:MSLE - Free Report) - Stock analysts at HC Wainwright upped their Q2 2026 EPS estimates for shares of Satellos Bioscience in a report issued on Monday, March 30th. HC...

FY2030 Earnings Forecast for MSLE Issued By HC Wainwright

Satellos Bioscience Inc. (NASDAQ:MSLE - Free Report) - Analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Satellos Bioscience in a research note issued to investors on Monday, March 30th. HC Wainwright analyst A. He expects that the company will earn $0.34 per share...

Satellos Bioscience (NASDAQ:MSLE) Price Target Raised to $11.00

HC Wainwright boosted their price objective on shares of Satellos Bioscience from $1.20 to $11.00 and gave the stock a "buy" rating in a research report on Monday...

Satellos Bioscience (NASDAQ:MSLE) Releases Earnings Results

Satellos Bioscience (NASDAQ:MSLE - Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.36...

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

Why MSLE Stock Gave Up All Nasdaq Debut Gains And Fell 8% After Hours

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

MSLE Satellos Bioscience Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest MSLE News